Renalytix uses cookies to improve your experience. We respect your privacy and are committed to protecting your personal data. Read Privacy Notice.
Investors KidneyIntelX

Renalytix to Report Financial Results for Fourth Quarter and Full Year Fiscal 2023 on September 28

LONDON and SALT LAKE CITY, Sept. 25, 2023 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) will report its fourth quarter and full year fiscal 2023 financial results on Thursday, September 28, 2023, before market open. The Company will host a corresponding conference call and live


Read More
By |2024-04-22T23:25:57+00:0009.25.23|News|Comments Off on Renalytix to Report Financial Results for Fourth Quarter and Full Year Fiscal 2023 on September 28
Read More

Renalytix Appoints Senior Executive Howard Doran as Chief Business Officer

Doran Brings Significant Diagnostics Sector Experience to Lead the KidneyIntelX Global Sales Effort LONDON and SALT LAKE CITY, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX), the first company to commercialize an FDA approved artificial intelligence (AI) enabled


Read More
By |2024-04-22T23:25:58+00:0009.07.23|News|Comments Off on Renalytix Appoints Senior Executive Howard Doran as Chief Business Officer
Read More

Renalytix Clinical Advisory Board Formed to Support Broadening Use of KidneyintelX.dkd

World leading, multi-disciplinary experts advise on adoption of FDA authorized KidneyintelX.dkd across 14 million US patients with diabetes and chronic kidney disease LONDON and SALT LAKE CITY, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Renalytix plc  (LSE: RENX) (NASDAQ:RNLX) announces the launch of its


Read More
By |2024-04-22T23:25:58+00:0008.03.23|News|Comments Off on Renalytix Clinical Advisory Board Formed to Support Broadening Use of KidneyintelX.dkd
Read More

Renalytix Announces Middle East Distribution Agreement with Vector Pharma

Commercial availability of kidneyintelX.dkd™ expanded to an estimated  4 million DKD Patients in the Middle East Distribution agreement opens kidneyintelX.dkd testing to address early-stage kidney disease in region with one of the highest incidence rates for type 2 diabetes globally LONDON and SALT


Read More
By |2024-04-22T23:25:58+00:0007.21.23|News|Comments Off on Renalytix Announces Middle East Distribution Agreement with Vector Pharma
Read More

Late-Breaking KidneyIntelX Evidence Released at 83rd American Diabetes Association Scientific Sessions

12 Months KidneyIntelX™ in vitro prognostic testing continued to demonstrate clinical actions that lead to improvement in both diabetes (A1C reductions) and kidney health (eGFR slope improvement) in patients with Type 2 Diabetes and Chronic Kidney Disease LONDON and SALT LAKE CITY, July 07, 2023


Read More
By |2024-04-22T23:25:59+00:0007.07.23|News|Comments Off on Late-Breaking KidneyIntelX Evidence Released at 83rd American Diabetes Association Scientific Sessions
Read More

Renalytix Appoints Financial Executive Catherine Coste to its Board of Directors

LONDON and SALT LAKE CITY, July 03, 2023 (GLOBE NEWSWIRE) -- Renalytix plc  (NASDAQ: RNLX) (LSE: RENX), the first company to commercialize an FDA approved artificial intelligence (AI) enabled prognostic blood test for individuals with Type 2 diabetes and chronic kidney disease, announces the


Read More
By |2024-04-22T23:25:59+00:0007.03.23|News|Comments Off on Renalytix Appoints Financial Executive Catherine Coste to its Board of Directors
Read More

FDA Grants De Novo Marketing Authorization for KidneyIntelX.dkd to Assess Risk of Progressive Kidney Function Decline in Adults with Diabetes and Early-Stage Kidney Disease

Simple Blood Test Aids Risk Assessment for Approximately 14 Million Eligible Patients  in the United States Diabetic Kidney Disease is the Leading Cause of End Stage Kidney Disease in the United States LONDON and SALT LAKE CITY, June 29, 2023 (GLOBE NEWSWIRE) -- Renalytix plc  (LSE: RENX)


Read More
By |2024-04-22T23:26:00+00:0006.29.23|News|Comments Off on FDA Grants De Novo Marketing Authorization for KidneyIntelX.dkd to Assess Risk of Progressive Kidney Function Decline in Adults with Diabetes and Early-Stage Kidney Disease
Read More

KidneyIntelX™ Clinical Decision Impact / Validation and Health Economic Data to be Presented at Upcoming Scientific Conferences

Four new data presentations, including late breaking clinical study data, underscores the value of KidneyIntelX testing in helping slow progression of chronic kidney disease in type 2 diabetes patients LONDON and SALT LAKE CITY, June 15, 2023 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE:


Read More
By |2024-04-22T23:26:00+00:0006.15.23|News|Comments Off on KidneyIntelX™ Clinical Decision Impact / Validation and Health Economic Data to be Presented at Upcoming Scientific Conferences
Read More

Renalytix Reports Financial Results for Third Quarter of Fiscal Year 2023

LONDON and SALT LAKE CITY, June 09, 2023 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care, today


Read More
By |2024-04-22T23:26:01+00:0006.09.23|News|Comments Off on Renalytix Reports Financial Results for Third Quarter of Fiscal Year 2023
Read More

Renalytix to Report Third Quarter Fiscal Year 2023 Financial Results on June 9

LONDON and SALT LAKE CITY, June 05, 2023 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) will report its third quarter fiscal year 2023 financial results on Friday, June 9, 2023, before market open. The Company will host a corresponding conference call and live webcast to discuss the


Read More
By |2024-04-22T23:26:01+00:0006.05.23|News|Comments Off on Renalytix to Report Third Quarter Fiscal Year 2023 Financial Results on June 9
Read More

Why

Solutions

About

Latest News, Blogs & More

Connect

Investors

kidneyintelX.dkd

FOLLOW US

© 2024 Renalytix

Renalytix Clinical Laboratories:
New York City, NY

Client Service: 1-888-203-2725
Copyright © 2024

Go to Top